USFDA concludes PAI at Emcure Pharmaceuticals’ Gujarat manufacturing facility

Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 544210 | NSE: EMCURE

10 Jul 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Emcure Pharmaceuticals’ manufacturing facility (Oncology) located at Sanand, Ahmedabad, Gujarat. The said inspection was conducted from June 30, 2025 to July 08, 2025. The inspection concluded without issuance of Form 483 (zero observations).

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Peers

Company Name	CMP
Sun Pharma. Inds.	1842.00
Dr. Reddys Labs.	1161.00
Cipla	1365.00
Lupin	2096.00
Zydus Lifesciences	1119.50
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.